2 NIPER faculty members included in CDSCO expert panel to evaluate herbal drugs

Published On 2018-08-18 03:30 GMT   |   Update On 2021-08-19 05:33 GMT

Mohali: Two faculty members of National Institute of Pharmaceutical Education and Research (NIPER) here have been included in an expert panel set up by the Central Drugs Standard Control Organisation (CDSCO) to evaluate new herbal drugs for their regulatory approval.


Arvind K Bansal, the head of NIPER's Pharmaceutics Department and Saranjit Singh, the head of its Pharmaceutical Analysis Department are among the 12 experts who will evaluate the manufacturing, purification, quality control and toxicological data of the new herbal drugs, also called phytopharmaceuticals, said NIPER in a statement.


The expert panel is mandated to advise the Drugs Controller General of India (DCGI) on evaluation of "chemistry-manufacturing control data" including identification, authentication, and source of plants used for extraction, purification, formulation, and manufacturing of herbal drugs for their approval.


The expert committee would also be engaged in the preparation of guidelines for marketing approval of new phyto-pharmaceuticals of different therapeutic categories, the NIPER's release said.


Other experts include Delhi Pharmaceutical Sciences & Research University's Vice Chancellor Ramesh K Goyal, Indian Institute of Integrative Medicine Director Ram Viswakarma and IIT-BHU's Professor Siva Hemalatha of its Department of Pharmaceutical Engineering.

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News